| MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (NCT03865511) | Nantes University Hospital | 2019-04-09 |
| Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (NCT03647163) | Vyriad, Inc. | 2019-04-09 |
| CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). (NCT03848611) | AnewPharma | 2019-04-02 |
| BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics (NCT04136470) | Ardigen | 2019-04-01 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (NCT03846310) | Arcus Biosciences, Inc. | 2019-04-01 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (NCT03860272) | Agenus Inc. | 2019-03-20 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer (NCT03819387) | Nitto BioPharma, Inc. | 2019-03-18 |
| Recurrence Monitoring in NSCLC Using Circulating Tumor DNA (NCT03878537) | Scripps Translational Science Institute | 2019-03-14 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) (NCT03829332) | Merck Sharp & Dohme LLC | 2019-03-13 |
| Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies (NCT03877250) | Memorial Sloan Kettering Cancer Center | 2019-03-08 |
| Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients (NCT03874000) | Tianjin Medical University Cancer Institute and Hospital | 2019-03-08 |
| A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer (NCT04641754) | Qilu Pharmaceutical Co., Ltd. | 2019-03-07 |
| Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC (NCT03998085) | The First Hospital of Jilin University | 2019-03-05 |
| A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03743051) | Helsinn Healthcare SA | 2019-03-05 |
| Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma (NCT03827070) | Center Trials & Treatment Europe | 2019-03-05 |
| A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC (NCT03823807) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2019-03-01 |
| Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC (NCT03900117) | Sun Yat-sen University | 2019-03-01 |
| Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive (NCT03790397) | Fundación GECP | 2019-02-26 |
| Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon) (NCT04857970) | Centre Hospitalier Universitaire de Besancon | 2019-02-20 |
| Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer (NCT03574220) | Case Comprehensive Cancer Center | 2019-02-19 |
| A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer (NCT03903887) | Sun Yat-sen University | 2019-02-19 |
| A Study of a Personalized Neoantigen Cancer Vaccine (NCT03639714) | Gritstone bio, Inc. | 2019-02-13 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study (NCT03576937) | University Health Network, Toronto | 2019-02-12 |
| A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (NCT03782207) | Hoffmann-La Roche | 2019-02-07 |
| A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer (NCT03807778) | Takeda | 2019-02-04 |
| A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients (NCT03849768) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-02-01 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC (NCT03611738) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-01 |
| Dose Individualization of Pemetrexed - IMPROVE-I (NCT03656549) | Radboud University Medical Center | 2019-02-01 |
| Dose Individualization of Pemetrexed - IMPROVE-III (NCT03655834) | Radboud University Medical Center | 2019-02-01 |
| Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer (NCT03840408) | Shanghai 10th People's Hospital | 2019-01-31 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer (NCT03801304) | University Hospital, Brest | 2019-01-24 |
| Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (NCT03808480) | National Cancer Center, Korea | 2019-01-23 |
| Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance (NCT03833934) | Addario Lung Cancer Medical Institute | 2019-01-23 |
| Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study (NCT04069663) | University Hospital, Grenoble | 2019-01-22 |
| Safety and Efficacy of Lorbrena (NCT03844464) | Pfizer | 2019-01-21 |
| Study of NEO-201 in Solid Tumors Expansion Cohorts (NCT03476681) | Precision Biologics, Inc | 2019-01-18 |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease (NCT03808337) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (NCT03735290) | Mendus | 2019-01-14 |
| Molecular Profiling Project (NCT04025515) | National Cancer Centre, Singapore | 2019-01-11 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors (NCT03637803) | 4D pharma plc | 2019-01-10 |
| A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer (NCT03258788) | The Christie NHS Foundation Trust | 2019-01-03 |
| Lung Heart Rate Variability (NCT03674450) | Abramson Cancer Center at Penn Medicine | 2019-01-02 |
| Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (NCT03798743) | Hunan Province Tumor Hospital | 2019-01-01 |
| Lindera Obtusiloba for Non-small Cell Lung Cancer (NCT04348149) | Jun-Yong Choi | 2018-12-28 |
| A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT03735121) | Hoffmann-La Roche | 2018-12-27 |
| Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (NCT03631199) | Novartis Pharmaceuticals | 2018-12-21 |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2018-12-21 |
| Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (NCT03726736) | Yong Fang | 2018-12-21 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| Continued Access to RXDX-105 (NCT03784378) | Memorial Sloan Kettering Cancer Center | 2018-12-14 |
| A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer (NCT03789604) | CStone Pharmaceuticals | 2018-12-13 |
| A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (NCT03797391) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2018-12-13 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (NCT03800134) | AstraZeneca | 2018-12-06 |
| NGS Combined With RNAseq on Tumor Immune Escape in NSCLC (NCT03764917) | Shanghai Pulmonary Hospital, Shanghai, China | 2018-12-01 |
| The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) (NCT03811054) | Beijing Chest Hospital | 2018-12-01 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (NCT03736837) | Tianjin Medical University Cancer Institute and Hospital | 2018-12-01 |
| Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation (NCT03754530) | Betta Pharmaceuticals Co., Ltd. | 2018-12-01 |
| McMaster Catheterization for Thoracoscopic Surgery Study (NCT02640326) | McMaster University | 2018-12-01 |
| Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients (NCT02696525) | Peking University People's Hospital | 2018-12-01 |
| Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC (NCT03674827) | Pfizer | 2018-11-27 |
| Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE) (NCT03198468) | Uptake Medical Technology, Inc. | 2018-11-21 |
| MGC018 With or Without MGA012 in Advanced Solid Tumors (NCT03729596) | MacroGenics | 2018-11-21 |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China (NCT03565003) | Jacobio Pharmaceuticals Co., Ltd. | 2018-11-20 |
| Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment (NCT03706625) | Assistance Publique - Hôpitaux de Paris | 2018-11-20 |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative (NCT03765775) | First Hospital of Shijiazhuang City | 2018-11-20 |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC (NCT03711422) | National Cancer Centre, Singapore | 2018-11-16 |
| A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (NCT02905591) | Joseph J. Cullen, MD, FACS | 2018-11-16 |
| Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） (NCT03735264) | The Affiliated Hospital of Qingdao University | 2018-11-15 |
| PDX Models From EGFR Mutant Tumors (NCT03872440) | Addario Lung Cancer Medical Institute | 2018-11-14 |
| Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients (NCT03664843) | First Hospital of Shijiazhuang City | 2018-11-09 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (NCT03732001) | China Medical University, China | 2018-11-08 |
| ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (NCT03445000) | ETOP IBCSG Partners Foundation | 2018-11-06 |
| Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC) (NCT03700437) | Indiana University | 2018-11-02 |
| Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC (NCT03769129) | Second Affiliated Hospital of Guangzhou Medical University | 2018-11-01 |
| Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma (NCT03728374) | First Affiliated Hospital of Wenzhou Medical University | 2018-11-01 |
| Pharmacogenetics in Non Small Cell Lung Cancer (NCT03791151) | Ain Shams University | 2018-11-01 |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (NCT03653546) | Alpha Biopharma (Jiangsu) Co., Ltd. | 2018-10-29 |
| Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC (NCT03535363) | Case Comprehensive Cancer Center | 2018-10-26 |
| Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (NCT03463525) | AstraZeneca | 2018-10-24 |
| Daily vs. Non-Daily SBRT for NSCLC (NCT03624907) | University of Florida | 2018-10-19 |
| A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) (NCT03631784) | Merck Sharp & Dohme LLC | 2018-10-19 |
| Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (NCT03607188) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-10-18 |
| Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer (NCT03624309) | Hunan Cancer Hospital | 2018-10-15 |
| Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction (NCT03564054) | University of Florida | 2018-10-11 |
| Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer (NCT05226728) | Sun Yat-sen University | 2018-10-10 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (NCT03539536) | AbbVie | 2018-10-10 |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer (NCT03704688) | Memorial Sloan Kettering Cancer Center | 2018-10-09 |
| Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors (NCT03946007) | University Medical Center Groningen | 2018-10-04 |
| A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab (NCT03804554) | Bristol-Myers Squibb | 2018-10-03 |
| Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (NCT03573947) | Jeffrey Clarke | 2018-10-02 |
| M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03631706) | EMD Serono Research & Development Institute, Inc. | 2018-10-01 |